Suppr超能文献

危重症患者肠内免疫营养的前瞻性、随机、双盲、对照临床试验。盖伊医院重症监护组。

A prospective, randomized, double-blind, controlled clinical trial of enteral immunonutrition in the critically ill. Guy's Hospital Intensive Care Group.

作者信息

Atkinson S, Sieffert E, Bihari D

机构信息

Department of Intensive Care, Guy's Hospital, London, UK.

出版信息

Crit Care Med. 1998 Jul;26(7):1164-72. doi: 10.1097/00003246-199807000-00013.

Abstract

OBJECTIVE

To assess the effects of enteral immunonutrition (IMN) on hospital mortality and length of stay in a heterogeneous group of critically ill patients.

DESIGN

Prospective, randomized, double-blind, controlled clinical trial with an a priori subgroup analysis according to the volume of feed delivered in the first 72 hrs of intensive care unit (ICU) admission.

SETTING

A 13-bed adult general ICU in a London teaching hospital.

PATIENTS

A total of 398 patients were enrolled and data from 390 patients (IMN = 193, control = 197) were used for an intention-to-treat analysis. There were 369 patients (IMN = 184, control = 185) who actually received some enteral nutrition, of whom 101 patients (IMN = 50, control = 51) received >2.5 L within 72 hrs of ICU admission. This latter group was defined as the successful "early enteral nutrition" group.

INTERVENTIONS

Within 48 hrs of ICU admission, patients were randomized to receive either the IMN Impact (Novartis Nutrition), an enteral feed supplemented with arginine, purine nucleotides and omega-3 fatty acids, or an isocaloric, isonitrogenous control enteral feed.

MEASUREMENTS AND RESULTS

There was no significant difference in hospital mortality rate between the two groups on an intention-to-treat analysis (Impact group 48%, control group 44%) nor in any other predefined subgroup analysis. However, patients randomized to receive the IMN had higher Acute Physiology and Chronic Health Evaluation II scores (20.1 +/- 7.1 vs. 18.7 +/- 7.1 [p = .07] intention-to-treat [n = 390]; 20.1 +/- 7.2 vs. 18.5 +/- 7.1 [p = .04] received feed [n = 369]). Of the 101 patients achieving early enteral nutrition, those patients fed with the IMN had a significant reduction in their requirement for mechanical ventilation compared with controls (median duration of ventilation 6.0 and 10.5 days, respectively, p = .007) with an associated reduction in the length of hospital stay (medians 15.5 and 20 days, respectively, p = .03).

CONCLUSION

While the administration of enteral IMN to a general, critically ill population did not affect mortality, those patients in whom it was possible to achieve early enteral nutrition with Impact had a significant reduction in the morbidity of their critical illness.

摘要

目的

评估肠内免疫营养(IMN)对一组异质性重症患者的医院死亡率和住院时间的影响。

设计

前瞻性、随机、双盲、对照临床试验,并根据重症监护病房(ICU)入院后前72小时的喂养量进行预先设定的亚组分析。

地点

伦敦一家教学医院的一间拥有13张床位的成人综合ICU。

患者

共纳入398例患者,390例患者(IMN组 = 193例,对照组 = 197例)的数据用于意向性分析。有369例患者(IMN组 = 184例,对照组 = 185例)实际接受了一些肠内营养,其中101例患者(IMN组 = 50例,对照组 = 51例)在ICU入院后72小时内接受的喂养量>2.5升。后一组被定义为成功的“早期肠内营养”组。

干预措施

在ICU入院后48小时内,患者被随机分配接受IMN Impact(诺华营养公司生产),一种添加了精氨酸、嘌呤核苷酸和ω-3脂肪酸的肠内营养制剂,或等热量、等氮量的对照肠内营养制剂。

测量指标及结果

在意向性分析中,两组的医院死亡率无显著差异(Impact组为48%,对照组为44%),在任何其他预先定义的亚组分析中也无显著差异。然而,随机接受IMN的患者急性生理与慢性健康状况评分II更高(意向性分析时,[n = 390],20.1±7.1对18.7±7.1 [p = 0.07];接受喂养的患者中,[n = 369],20.1±7.2对18.5±7.1 [p = 0.04])。在101例实现早期肠内营养的患者中,与对照组相比,接受IMN喂养的患者机械通气需求显著减少(通气中位持续时间分别为6.0天和10.5天,p = 0.007),住院时间也相应缩短(中位数分别为15.5天和20天,p = 0.03)。

结论

虽然对一般重症患者给予肠内IMN并未影响死亡率,但那些能够通过Impact实现早期肠内营养的患者,其危重症的发病率显著降低。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验